Suita-shi

Running trials

• Not yet recruiting

  An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of ALXN2220 in Adults With Transthyretin Amyloid Cardiomyopathy

  NCT07789483· Phase 3· Source

• Recruiting

  Torvutatug Samrotecan With or Without Bevacizumab as Maintenance Treatment of Platinum-sensitive Relapsed Epithelial Ovarian Cancer

  NCT07816666· Phase 3· Source

• Recruiting

  Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)

  NCT07711002· Phase 3· Source

• Recruiting

  A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.

  NCT07753993· Phase 3· Source

• Recruiting

  A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight

  NCT07784270· Phase 3· Source

• Recruiting

  A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin

  NCT07662135· Phase 3· Source

• Recruiting

  A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM

  NCT07667803· Phase 3· Source

• Recruiting

  Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT

  NCT07764978· Phase 3· Source

• Recruiting

  AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)

  NCT07611110· Phase 3· Source

• Recruiting

  A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)

  NCT07221253· Phase 3· Source

• Recruiting

  Real-Life Clinical Efficacy of Acoramidis in Participants With ATTR-CM and Association With Cardiac Biomarkers

  NCT07306949· Phase 4· Source

• Recruiting

  A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma

  NCT07069712· Phase 2· Source

• Active, not recruiting

  A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With HeFH

  NCT07000136· Phase 3· Source

• Recruiting

  Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma

  NCT06921785· Phase 3· Source

• Recruiting

  Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin

  NCT06677060· Phase 3· Source

• Recruiting

  A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer

  NCT06764875· Phase 3· Source

• Recruiting

  Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer

  NCT06380751· Phase 3· Source

• Active, not recruiting

  Study of ALXN2220 Versus Placebo in Adults With ATTR-CM

  NCT06183931· Phase 3· Source

• Active, not recruiting

  Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)

  NCT06109779· Phase 3· Source

• Active, not recruiting

  Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents

  NCT06120491· Phase 3· Source

• Active, not recruiting

  Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY)

  NCT05925803· Phase 3· Source

• Active, not recruiting

  A Trial to Learn How Safe AZD9550 Monotherapy and Combined With AZD6234 is in People With or Without Type 2 Diabetes Who Are Living With Obesity and Overweight

  NCT06151964· Phase 1/2· Source

• Recruiting

  Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)

  NCT06079671· Phase 3· Source

• Active, not recruiting

  Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis

  NCT05556096· Phase 3· Source

• Recruiting

  Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

  NCT05489211· Phase 2· Source

• Active, not recruiting

  Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)

  NCT04862663· Phase 3· Source

• Active, not recruiting

  A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease

  NCT04711252· Phase 3· Source

• Active, not recruiting

  A Study of T-DXd for the Treatment of Solid Tumors Harboring HER2 Activating Mutations

  NCT04639219· Phase 2· Source

• Active, not recruiting

  A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors

  NCT04482309· Phase 2· Source

• Active, not recruiting

  Durvalumab or Placebo in Combination With Gemcitabine/Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer (TOPAZ-1)

  NCT03875235· Phase 3· Source

• Active, not recruiting

  Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer

  NCT03682068· Phase 3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Gastric and oesophageal cancer3 recruiting
• Liver and biliary tract cancer3 recruiting
• Prostate cancer3 recruiting
• Type 2 diabetes3 recruiting
• Amyloidosis2 recruiting
• Chronic kidney disease2 recruiting
• Obesity2 recruiting
• Ovarian cancer2 recruiting
• Cervical cancer1 recruiting
• Childhood cancers1 recruiting
• Colorectal cancer1 recruiting
• Endometrial cancer1 recruiting
• Heart failure1 recruiting
• Metastatic breast cancer1 recruiting
• Multiple myeloma1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  A Weight Loss Study Evaluating Subcutaneous Treatment With AZD9550 and AZD6234 in Combination Against Placebo or Each of the Drugs Alone

  NCT06862791· Phase 2· Source

• Completed

  Effects of AZD5004 in Adults Who Are Living With Obesity or Overweight With at Least 1 Weight-related Comorbidity

  NCT06579092· Phase 2· Source

• Completed

  A Study in Participants With Obesity or Overweight With at Least One Weight-related Comorbidity

  NCT06595238· Phase 2· Source

• Completed

  A Study to Evaluate the Safety and Efficacy of Cotadutide Given by Subcutaneous Injection in Adult Participants With Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis

  NCT05364931· Phase 2· Source

• Completed

  A Phase 3 Study of ALXN2060 in Japanese Participants With Symptomatic ATTR-CM

  NCT04622046· Phase 3· Source

• Terminated

  A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205

  NCT04241068· Phase 3· Source

• Completed

  Durvalumab Long-Term Safety and Efficacy Study

  NCT04078152· Phase 4· Source

• Completed

  Long-Term Evaluation of BIIB067 (Tofersen)

  NCT03070119· Phase 3· Source

• Completed

  A Global Study to Compare the Effects of Fulvestrant and Arimidex in a Subset of Patients With Breast Cancer.

  NCT01602380· Phase 3· Source